DGAP-News: Resolutions of the Annual General Meeting of Evotec AG
(firmenpresse) - DGAP-News: Evotec AG / Key word(s): AGM/EGM
Resolutions of the Annual General Meeting of Evotec AG
12.06.2013 / 16:37
---------------------------------------------------------------------
- Actions of Management Board and Supervisory Board approved
- Dr Walter Wenninger becomes new Chairman of the Supervisory Board
- Dr Claus Braestrup elected as new member of the Supervisory Board
- Fixed remuneration for the Supervisory Board concluded
Hamburg - 12 June 2013: Shareholders of Evotec AG (Frankfurt Stock
Exchange: EVT, TecDAX, ISIN: DE0005664809) today approved the actions of
the members of the Management Board and the Supervisory Board for the
fiscal year 2012 at the Annual General Meeting.
The Chief Executive Officer of Evotec AG, Dr Werner Lanthaler, presented
the Company's performance for the year 2012 and provided the shareholders
with an update on the topic innovation efficiency within Action Plan 2016.
Furthermore, the Annual General Meeting elected Dr Claus Braestrup as new
member of the Supervisory Board. Dr Braestrup has extensive experience in
executive-level functions at international pharmaceutical companies - among
others as former President and CEO and Head of Research and Development of
Lundbeck A/S and as Vice President for pharmaceutical research at Novo
Nordisk A/S. His special skills in the area of drug research are of great
value for his task within the Supervisory Board.
Dr Braestrup succeeds Dr FlemmingØrnskov until the completion of the
Annual General Meeting 2014. DrØrnskov resigned as member and Chairman of
the Supervisory Board upon conclusion of the Annual General Meeting 2013.
In a subsequent meeting of the Supervisory Board, Dr Walter Wenninger,
former Deputy Chairman of the Supervisory Board, was elected as Chairman of
the Supervisory Board and Mr Roland Oetker was elected as his Deputy
Chairman.
'I'd like to express my sincere gratitude to DrØrnskov, also on behalf of
my colleagues in the Management Board, for his constructive and successful
collaboration over the last years. We wish him all the best for realising
his professional and personal objectives', said Dr Werner Lanthaler, Chief
Executive Officer of Evotec. 'At the same time, I'd like to warmly welcome
Dr Claus Braestrup to the Evotec Supervisory Board.'
The Annual General Meeting also approved the proposal of the Management
Board and the Supervisory Board to change the remuneration of the
Supervisory Board to a fixed remuneration in form of cash compensation from
fiscal year 2013 onwards. Moreover, the Annual General Meeting passed all
of the other agenda items requiring shareholders' approval, thereunder the
resolution on single amendments of the articles of association and the
appointment of KPMG as the auditor for fiscal year 2013.
At the ordinary Annual General Meeting 2013 of Evotec AG, 40.5% of the
voting capital was present.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in keytherapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca
and Ono Pharmaceutical. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim,
MedImmune and Andromeda (Teva) in the field of diabetes, with Janssen
Pharmaceuticals in the field of depression and with Roche in the field of
Alzheimer's disease. For additional information please go to
www.evotec.com.
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, Head of Corporate Communications, Phone:
+49.(0)40.56081-255, gabriele.hansen(at)evotec.com
End of Corporate News
---------------------------------------------------------------------
12.06.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info(at)evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
216140 12.06.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 12.06.2013 - 16:37 Uhr
Sprache: Deutsch
News-ID 269060
Anzahl Zeichen: 7826
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 346 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Resolutions of the Annual General Meeting of Evotec AG"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
